

AMENDMENTS TO THE CLAIMS


Claims 16-21 have been amended. A listing of the claims follows and replaces all prior listing of the claims.

LISTING OF THE CLAIMS

Need more work


Claims 1-15 (Cancelled).

Claim 16 (Currently amended): A β -lactamase resistant cephalosporin ester compound and salts thereof represented by formula (I) as follows:




wherein,

when R is




, R₁ is —CH_3 (YR-1)

when R is




, R₁ is $\text{—CH}_2\text{C(=O)NH}_2$ (YR-2)

when R is




, R₁ is —CH₃ (YR-3)

when R is




, R₁ is —CH₃ (YR-4)

when R is



, R₁ is —CH₃ (YR-5)

or, when R is



, R₁ is —Cl (YR-6)

Claim 17 (Currently amended): A pharmaceutical salt of the β -lactamase resistant cephalosporin ester compound according to claim 16.

Claim 18 (Currently amended): The pharmaceutical salt of the β -lactamase resistant cephalosporin ester compound according to claim 17, wherein the pharmaceutical salt is an inorganic salt or an organic acid salt.

Claim 19 (Currently amended): The pharmaceutical salt of the β -lactamase resistant cephalosporin ester compound according to claim 18, wherein the inorganic salt or organic acid salt is at least one of a hydrochloride, a sulphate, a *p*-toluenesulfonate, a tartrate, a maleate and a lactate.

Claim 20 (Currently amended): A method for treating infection, comprising:

administering orally to a patient in need of treatment, an effective amount of a composition comprising the β -lactamase resistant cephalosporin ester compound according to claim 16 as an effective ingredient.

Claim 21 (Currently amended): A composition, comprising:

the β -lactamase resistant cephalosporin ester compound according to claim 16; and

a physiologically acceptable carrier.


Claim 22 (Previously presented): A method for treating infection, comprising:

administering orally to a patient in need of treatment, an effective amount of a composition comprising the pharmaceutical salt according to claim 17 as an effective ingredient.

Claim 23 (Previously presented): A composition, comprising:


the pharmaceutical salt according to claim 17; and
a physiologically acceptable carrier.

Claim 24 (Allowed): A intermediate compound represented by formula (IV) as follows:




wherein, $R_1 = \text{CH}_3$ or Cl ; $R_2 =$, , or

Claim 25 (Previously presented): A pharmaceutical salt of a β -lactamase resistant cephalosporin ester compound in which the β -lactamase resistant cephalosporin ester compound is represented by formula (I) as follows:




wherein,

when R is




, R₁ is —CH₃ (YR-1)

when R is




, R₁ is —CH₂OC(=O)NH₂ (YR-2)

when R is




, R₁ is —CH₃ (YR-3)

when R is




, R₁ is —CH₃ (YR-4)

when R is



, R₁ is —CH₃ (YR-5)

or, when R is



, R₁ is —Cl (YR-6), and

wherein the pharmaceutical salt is an inorganic salt or an organic acid salt of the β -lactamase resistant cephalosporin ester compound represented by formula (I) and is at least

one of a hydrochloride, a sulphate, a *p*-toluenesulfonate, a tartrate, a maleate and a lactate.

Claim 26 (Previously presented): A method for treating infection, comprising:

administering orally to a patient in need of treatment, an effective amount of an antibiotic composition comprising the pharmaceutical salt according to claim 25 as an effective ingredient.

Claim 27 (Previously presented): An antibiotic composition, comprising:

the pharmaceutical salt according to claim 25; and
an incipient suitable for oral administration.